caa a22 4500 605476853 CHVBK 20210128100358.0 cr unu---uuuuu 210128e20151201xx s 000 0 eng 10.1007/s00787-015-0725-1 doi (NATIONALLICENCE)springer-10.1007/s00787-015-0725-1 Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial [Elektronische Daten] [Marie Stentebjerg-Olesen, Stephen Ganocy, Robert Findling, Kiki Chang, Melissa DelBello, John Kane, Mauricio Tohen, Pia Jeppesen, Christoph Correll] In adults with schizophrenia, early response/non-response (ER/ENR) to antipsychotics at 2weeks robustly predicts ultimate response/non-response (UR/UNR). However, less data about the predictive value of ER/ENR exist in adolescents with schizophrenia. Post hoc analysis of a 6-week trial in adolescents aged 13-17 with schizophrenia were randomized 2:1 to olanzapine or placebo. ER was defined as≥20% reduction in Brief Psychiatric Rating Scale-children (BPRS-C) total score at week 2 (ER2) or 3 (ER3); UR was defined with increasing stringency as total BPRS-C score reduction≥20,≥30,≥40 or≥50%; remission was defined cross-sectionally using Andreasen et al. (2005) criteria. By week 2 (n=69) and 3 (n=66), olanzapine-treated youth achieved 73.3 and 85.5% of their overall BPRS-C score reduction at 6weeks last observation carried forward. ER and ENR patients did not differ significantly regarding baseline demographic, illness and treatment variables. ER 2 (frequency=68.1%) and ER 3 (frequency=65.2%) significantly predicted UR and remission (p=0.0044-p<0.0001), with ER3 having more predictive power. A≥20% BPRS-C reduction threshold for ER had best predictive validity (area under the curve=0.88-0.92). At 6weeks, patients with ER had significantly greater improvements in BPRS-C, Clinical Global Impressions Improvement and Severity scores, greater cross-sectional remission and less all-cause discontinuation (p=0.047-p<0.0001). Adverse event profiles were similar in the ER and ENR groups. Adolescents with schizophrenia experienced the majority of symptomatic improvement early during olanzapine treatment. ER predicted UR and remission, with ER3 having best predictive power. A≥20% improvement threshold for defining ER was confirmed as a robust outcome indicator. Springer-Verlag Berlin Heidelberg, 2015 Schizophrenia nationallicence Adolescents nationallicence Response nationallicence Remission nationallicence Prediction nationallicence Stentebjerg-Olesen Marie Mental Health Centre for Child and Adolescent Psychiatry, Copenhagen University Hospital, Glostrup, Denmark aut Ganocy Stephen Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA aut Findling Robert Johns Hopkins University and the Kennedy Krieger Institute, Baltimore, MD, USA aut Chang Kiki Stanford University School of Medicine, Stanford, CA, USA aut DelBello Melissa University of Cincinnati, Cincinnati, OH, USA aut Kane John Department of Psychiatry, The Zucker Hillside Hospital, Psychiatry Research, North Shore, Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut Tohen Mauricio Department of Psychiatry, University of New Mexico Health Science Center, Albuquerque, NM, USA aut Jeppesen Pia Mental Health Centre for Child and Adolescent Psychiatry, Copenhagen University Hospital, Glostrup, Denmark aut Correll Christoph Department of Psychiatry, The Zucker Hillside Hospital, Psychiatry Research, North Shore, Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut European Child & Adolescent Psychiatry Springer Berlin Heidelberg 24/12(2015-12-01), 1485-1496 1018-8827 24:12<1485 2015 24 787 https://doi.org/10.1007/s00787-015-0725-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00787-015-0725-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Stentebjerg-Olesen Marie Mental Health Centre for Child and Adolescent Psychiatry, Copenhagen University Hospital, Glostrup, Denmark aut NATIONALLICENCE 700 1- Ganocy Stephen Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA aut NATIONALLICENCE 700 1- Findling Robert Johns Hopkins University and the Kennedy Krieger Institute, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Chang Kiki Stanford University School of Medicine, Stanford, CA, USA aut NATIONALLICENCE 700 1- DelBello Melissa University of Cincinnati, Cincinnati, OH, USA aut NATIONALLICENCE 700 1- Kane John Department of Psychiatry, The Zucker Hillside Hospital, Psychiatry Research, North Shore, Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut NATIONALLICENCE 700 1- Tohen Mauricio Department of Psychiatry, University of New Mexico Health Science Center, Albuquerque, NM, USA aut NATIONALLICENCE 700 1- Jeppesen Pia Mental Health Centre for Child and Adolescent Psychiatry, Copenhagen University Hospital, Glostrup, Denmark aut NATIONALLICENCE 700 1- Correll Christoph Department of Psychiatry, The Zucker Hillside Hospital, Psychiatry Research, North Shore, Long Island Jewish Health System, 75-59 263rd Street, 11004, Glen Oaks, NY, USA aut NATIONALLICENCE 773 0- European Child & Adolescent Psychiatry Springer Berlin Heidelberg 24/12(2015-12-01), 1485-1496 1018-8827 24:12<1485 2015 24 787